Life sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.
Approved
Claim This Podcastby Alex Kesin and Matthew Pech
4.8(25 reviews)
3 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
Life sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.
Language
🇺🇲
Publishing Since
1/30/2026
Reach the team behind Approved
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
May 14, 2026
Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time
<p><strong>Keytruda</strong> is Merck's $31 billion a year <strong>PD-1 inhibitor</strong> and the best-selling cancer drug of all time. In Episode 3 of Approved, Alex Kesin and Matthew Pech trace the development of <strong>pembrolizumab</strong> , featuring interviews the scientists who drove the program forward : co-inventors <strong>Gregory Carven</strong> and <strong>Michel Streuli</strong>, and former <strong>Merck</strong> oncology CMO <strong>Roy Baynes</strong>.</p><p>Topics include preclinical <strong>PD1 / CTLA-4 checkpoint biology</strong> that brought industry attention to the target (Jim Allison's CTLA-4 work and Tasuku Honjo's PD-1 discovery); how pembro started as a failed rheumatoid arthritis antibody program at a Dutch subsidiary of a paint company; the two mega-mergers that nearly killed the program; the <strong>biomarker enrichment</strong> trial design behind KEYNOTE-024 that let Merck break BMS's lead in lung cancer; the 41-patient Johns Hopkins MSI-H trial behind the first tissue-agnostic FDA approval, and the <strong>Jimmy Carter</strong> melanoma case that brought pembrolizumab to the public conscious. The episode closes on what comes next for Merck: the 2028 patent cliff, the <strong>Keytruda QLEX</strong> subcutaneous launch, and efforts to find the next blockbuster checkpoint inhibitor, including Summit/Akeso's <strong>PD-1 / VEGF bispecific ivonescimab</strong>.</p><p>This episode is presented by <strong>JLL</strong>. Featuring Grant Dettmer on biotech real estate strategy.</p><p><strong>CHAPTERS</strong></p><p><br> 00:00:00 — Introduction: The Best-Selling Cancer Drug of All Time</p><p><br> 00:02:15 — Part One — A Century of Failed Cancer Immunotherapy</p><p><br> 00:04:17 — T Cells, CD28, and the Two-Signal Model of Immune Activation</p><p><br> 00:06:25 — Jim Allison's CTLA-4 Discovery and the Path to Yervoy</p><p><br> 00:12:03 — Tasuku Honjo Discovers PD-1: A Better Brake on T Cells</p><p><br> 00:14:26 — Lieping Chen and the PD-L1 Tumor Evasion Hypothesis</p><p><br> 00:16:26 — Part Two — Organon: The Dutch Paint-Company Subsidiary Behind Keytruda</p><p><br> 00:19:48 — How Michel Streuli Caught the Solid-Phase Screening Artifact</p><p><br> 00:22:09 — The Accidental Antagonist: From Rheumatoid Arthritis Drug to Cancer Drug</p><p><br> 00:26:34 — Sponsor: Grant Detmer (JLL) on Biotech Real Estate Strategy</p><p><br> 00:30:01 — Russian Nesting-Doll M&A: Schering-Plough Acquires Organon (2007)</p><p><br> 00:31:43 — The $41 Billion Merck–Schering-Plough Mega-Merger of 2009</p><p><br> 00:34:58 — Corporate Guerrilla Warfare: Four Scrappy Stunts That Saved Pembrolizumab</p><p><br> 00:39:32 — BioNovion's Spite-Company Bid to Buy Pembro Back</p><p><br> 00:42:10 — BMS at ASCO 2010: The Data Print That Revived Merck's PD-1 Program</p><p><br> 00:45:55 — Part Three — Roger Perlmutter Joins a Bleeding Merck (April 2013)</p><p><br> 00:50:48 — "Let Me Manage the Tigers": Ken Frazier Backs the All-In Bet on Pembrolizumab</p><p><br> 00:55:22 — Breakthrough Therapy Designation and Eric Rubin's Adaptive Trial Design</p><p><br> 00:58:25 — Keytruda's 2014 FDA Approval Erases BMS's Four-Year Lead</p><p><br> 01:00:24 — The Lung Cancer Battlefield and the PD-L1 Biomarker Bet</p><p><br> 01:02:19 — BMS vs. Merck: All-Comers vs. Biomarker-Enriched Trial Strategy</p><p><br> 01:08:18 — KEYNOTE-024 vs. CheckMate-026: The Trial That Decided the Category</p><p><br> 01:12:03 — Luis Diaz, MSI-H, and the Failed BMS Trial That Made Keytruda Tissue-Agnostic</p><p><br> 01:17:18 — KEYNOTE-189: Perlmutter's Bet on Combining Keytruda with Chemotherapy</p><p><br> 01:19:21 — Merck's Clinical Development Playbook: Basket Trials, Backwards March, External Collabs</p><p><br> 01:25:29 — Part Four — The IO Graveyard: TIGIT, CD47, IDO1, LAG-3 and Tens of Billions Incinerated</p><p><br> 01:30:23 — Why PD-1 Was the Only Checkpoint That Worked (Lieping Chen Revisited)</p><p><br> 01:33:32 — Part Five — Inside the Best-Selling Drug of All Time</p><p><br> 01:37:03 — "Build a Wall, High and Wide": Merck’s Commercial Strategy for Keytruda</p><p><br> 01:43:44 — Part Six — The Patent Cliff and Loss of Exclusivity in Pharma</p><p><br> 01:45:35 — Keytruda QLEX (Subcutaneous) and the Lifecycle Management Playbook</p><p><br> 01:50:23 — PD-1/VEGF Bispecifics: Ivonescimab, Summit Therapeutics, and the Next Threat</p><p><br> 01:55:31 — The Scorecard: Patient, Academic, and Financial Impact</p><p><br> 02:01:19 — Who Actually Profited: Merck vs. Organon vs. the Scientists Who Built the Drug</p><p><br> 02:05:54 — Epilogue: The Jimmy Carter Drug<br><strong></strong></p><p>Sources</p><p>Last updated: May 2026</p><p><strong><br>Essential reading</strong></p><ul><li><strong>Shaywitz, David.</strong> <a href="https://www.forbes.com/sites/davidshaywitz/2017/07/26/the-startling-history-behind-mercks-new-cancer-blockbuster/">"The Startling History Behind Merck's New Cancer Blockbuster."</a> Forbes, Jul 26, 2017. The definitive Organon-era origin story.</li><li><strong>Loftus, Peter.</strong> <a href="https://www.wsj.com/articles/why-merck-is-betting-big-on-one-cancer-drug-1523790000">"Why Merck Is Betting Big on One Cancer Drug."</a> WSJ, Apr 15, 2018. Source for Perlmutter's "whatever other projects you're working on, you can stop now."</li><li><strong>Lowe, Derek.</strong> <a href="https://www.science.org/content/blog-post/keytruda-story">"The Keytruda Story."</a> In the Pipeline.</li><li><strong>Graeber, Charles.</strong> <a href="https://www.amazon.com/Breakthrough-Immunotherapy-Race-Cure-Cancer/dp/1455568503">The Breakthrough</a>. Twelve, 2018.</li></ul><p><strong><br>Primary interviews</strong></p><p>Greg Carven, Michel Streuli, Roy Baynes — Approved podcast interviews (2026). Quotes attributed to these speakers come from these conversations unless otherwise noted.</p><p><strong><br>Foundational science</strong></p><ul><li>Stutman. <a href="https://www.science.org/doi/10.1126/science.183.4124.534">"Tumor development in athymic-nude mice."</a> Science (1974). The flawed experiment that killed tumor immunology for two decades.</li><li>Shankaran et al. <a href="https://www.nature.com/articles/35074122">"IFNγ and lymphocytes prevent primary tumour development."</a> Nature (2001). Schreiber's cancer immunoediting paper.</li><li>Leach, Krummel & Allison. <a href="https://www.science.org/doi/10.1126/science.271.5256.1734">"Antitumor immunity by CTLA-4 blockade."</a> Science (1996). Allison's '100-to-zero' experiment.</li><li>Ishida, Agata, Shibahara & Honjo. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC556898/">"Induced expression of PD-1."</a> EMBO J (1992). Honjo discovers PD-1.</li><li>Dong, Strome et al. <a href="https://www.nature.com/articles/nm730">"B7-H1 promotes T-cell apoptosis."</a> Nat Med (2002). Lieping Chen's PD-L1 immune-evasion paper.</li></ul><p><strong><br>Pivotal trials</strong></p><ul><li>Topalian et al. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1200690">"Anti-PD-1 ...</a></li></ul>
March 13, 2026
Episode #2: Geron
<p>Listen on <a href="https://open.spotify.com/episode/4COpXyTfI7jifq6da7wM52?si=EHI93INORPWlX8CabI6wcg">Spotify</a></p><p>Listen on <a href="https://podcasts.apple.com/us/podcast/episode-2-geron/id1873356046?i=1000755117965">Apple Podcasts</a></p><p>Listen on <a href="https://www.youtube.com/watch?v=ryeqeon5y4s">YouTube</a></p><p><strong>TABLE OF CONTENTS</strong></p><p>(00:00:00) - Introduction </p><p>(00:01:19) - Hayflick Limit </p><p>(00:08:30) - Michael West & Founding of Geron </p><p>(00:15:16) - Early Science & IP Strategy </p><p>(00:27:25) - Cloning the Telomerase Gene </p><p>(00:29:30) - Embryonic Stem Cells & Political Context </p><p>(00:44:21) - Okarma, West’s Departure & Corporate Turmoil </p><p>(01:05:08) - Spinal Cord Injury Trial </p><p>(01:30:45) - Pivot to Blood Cancer </p><p>(01:43:08) - Clinical & Commercial Drama</p><p>(02:01:45) - Legacy & Lessons</p><p><strong>CREDITS</strong></p><p>Co-hosted by Alex Kesin and Matthew Pech</p><p>Written, edited, and produced by Alex Kesin</p><p>Music: <a href="https://www.youtube.com/watch?v=4PoCA4taNyg">“Food”</a> by nerowski</p><p>* Special thanks to the team at <a href="https://www.nfx.com/">NFX</a> for the use of their recording studio.</p><p><strong>SOURCES</strong></p><p><strong>Last updated: March 2026</strong></p><p><strong>I. BOOKS</strong></p><p><a href="https://www.amazon.com/Merchants-Immortality-Pa-Stephen-Hall/dp/0618492216">Hall, Stephen S. Merchants of Immortality: Chasing the Dream of Human Life Extension. Houghton Mifflin, 2003.</a></p><p><a href="https://www.amazon.com/Inevitable-Collision-Inspiring-Research-Conservative-ebook/dp/B00NGRMSHC">Williams, Tory. Inevitable Collision: The Inspiring Story That Brought Stem Cell Research to Conservative America.Mary Ann Liebert, Inc., 2014.</a></p><p><strong>II. KEY SCIENTIFIC PUBLICATIONS</strong></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/13905658/">Hayflick, L. & Moorhead, P.S. “The serial cultivation of human diploid cell strains.” Experimental Cell Research 25 (1961): 585–621.</a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/7605428/">Kim, N.W. et al. “Specific association of human telomerase activity with immortal cells and cancer.” Science 266, no. 5193 (1994): 2011–2015.</a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/7544491/">Feng, J. et al. “The RNA component of human telomerase.” Science 269, no. 5228 (1995): 1236–1241.</a></p><p><a href="https://www.science.org/doi/10.1126/science.277.5328.955">Nakamura, T.M. et al. “Telomerase catalytic subunit homologs from fission yeast and human.” Science 277, no. 5328 (1997): 955–959.</a></p><p><a href="https://www.cell.com/cell/pdf/S0092-8674(00)80538-3.pdf">Meyerson, M. et al. “hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.” Cell 90, no. 4 (1997): 785–795.</a></p><p><a href="https://www.science.org/doi/10.1126/science.279.5349.349">Bodnar, A.G. et al. “Extension of life-span by introduction of telomerase into normal human cells.” Science 279, no. 5349 (1998): 349–352.</a></p><p><a href="https://www.science.org/doi/abs/10.1126/science.282.5391.1145">Thomson, J.A. et al. “Embryonic stem cell lines derived from human blastocysts.” Science 282, no. 5391 (1998): 1145–1147.</a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/12873987/">Asai, A. et al. “A novel telomerase template antagonist (GRN163) as a potential anticancer agent.” Cancer Research 63, no. 14 (2003): 3931–3939. </a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/15940257/">Herbert, B-S et al. “Effect of the lipid modification of GRN163.” Nature: Oncogene 24 (2005): 5765–5772. </a></p><p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1503479">Baerlochr, G. et al. “A pilot study of the telomerase inhibitor imetelstat for myelofibrosis.” New England Journal of Medicine 373 (2015): 908–919. </a></p><p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract">Platzbecker, U. et al. “Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge).” The Lancet (2024).</a></p><p><a href="https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70076">Lennox, A.L et al. “Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.” Clinical and Translational Science 17, no. 11 (2024).</a></p><p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4250218/">Scott, C. & Magnus, D. “Wrongful Termination: Lessons From the Geron Clinical Trial” Stem Cell Reports 3, no. 5 (2014): 721–723. </a></p><p><strong>III. REGULATORY & CLINICAL</strong></p><p><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217779s000lbl.pdf">Prescribing Information (Label) U.S. Food and Drug Administration. “RYTELO (imetelstat) for injection: Highlights of Prescribing Information.” NDA 217779. June 2024. </a></p><p><a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217779Orig1s000ltr.pdf">NDA Approval Letter U.S. Food and Drug Administration. “NDA Approval Letter: RYTELO (imetelstat) for injection.” NDA 217779. June 6, 2024. </a></p><p><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217779Orig1s000OtherR.pdf">Multi-Discipline Review & Evaluation U.S. Food and Drug Administration. “NDA Multi-Disciplinary Review and Evaluation: RYTELO (imetelstat).” NDA 217779Orig1s000. 2024. </a></p><p><a href="https://www.fda.gov/media/176966/download">ODAC Briefing Document U.S. Food and Drug Administration. “FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting, NDA 217779, Imetelstat.” March 14, 2024. </a></p><p><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217779Orig1s000RiskR.pdf">REMS/Risk Assessment Review U.S. Food and Drug Administration. “Risk Assessment and Risk Mitigation Review: RYTELO (imetelstat).” NDA 217779Orig1s000. 2024. </a></p><p><a href="https://ascopubs.org/doi/abs/10.1200/JCO-25-01369">Kim, N. et al. “US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.” The Oncologist (2025). PMID: 41135032.</a></p><p><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent">FDA. “FDA Approves Imetelstat for Low- to Intermediate-1-Risk Myelodysplastic Syndromes with Transfusion-Dependent Anemia.” June 2024.</a></p><p><a href="https://icer.org/wp-content/uploads/2024/08/MDS_Final-Report_For-Publication_08222024.pdf">ICER. “Evidence Report: Treatment for Anemia in Myelodysplastic Syndrome.” August 2024. </a></p><p><a href="https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-evidence-report-on-treatment-for-anemia-in-myelodysplastic-syndrome/">ICER. Press Release on Imetelstat Evidence Assessment. </a></p><p><a href="https://clinicaltrials.gov/study/NCT01217008">ClinicalTrials.gov. GRNOPC1 Phase I Trial. NCT01217008. </a></p><p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4553145/">Myelodysplastic Syndrome Epidemiology. PMC4553145.</a></p><p><a href="https://ashpublications.org/blood/article/142/26/2247/498176/Diagnosis-and-classification-of-myelodysplastic">MDS Risk and AML Progression. Blood (2023). </a></p><p><strong>IV. CORPORATE FILINGS & PRESENTATIONS</strong></p><p><a href="https://d18rn0p25nwr6d.cloudfront..."></a></p>
January 30, 2026
Episode #1: Amylin Pharmaceuticals
<p>Listen on <a href="https://open.spotify.com/show/66IeBvvuoDma0ysf8c4I8Z">Spotify</a></p><p>Listen on <a href="https://podcasts.apple.com/us/podcast/episode-1-amylin-pharmaceuticals/id1873356046?i=1000747377804">Apple Podcasts</a></p><p>Listen on <a href="https://www.youtube.com/watch?v=cddzPaXBzqg">YouTube</a></p><p><strong>TABLE OF CONTENTS</strong></p><p>(00:00:00) - Introduction</p><p>(00:04:40) - $50 of Dried Lizard Venom</p><p>(00:29:17) - Fax of Death</p><p>(00:43:04) - Sleeping Beauty Awakens</p><p>(00:52:07) - Carl Icahn Sends a Letter</p><p>(01:09:19) - Endgame</p><p>(01:13:40) - Postmortem & Playbook</p><p><strong>CREDITS</strong></p><p>Co-hosted by Alex Kesin and Matthew Pech </p><p>Written, edited, and produced by Alex Kesin</p><p>Music: <a href="https://www.youtube.com/watch?v=4PoCA4taNyg">“Food”</a> by nerowski</p><p>* Special thanks to the team at <a href="https://www.nfx.com/">NFX</a> for the use of their recording studio.</p><p>SOURCES</p><p><strong>Last updated: January 2026</strong></p><p><strong>I. PRIMARY DOCUMENTS</strong></p><p><strong>FDA Regulatory Documents</strong></p><p><strong>Symlin (pramlintide acetate) - NDA 21-332</strong></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_approv.PDF">Approval Letter & Package (March 16, 2005)</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_medr.PDF">Medical Review</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_statr.PDF">Statistical Review</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_biopharmr.PDF">Clinical Pharmacology & Biopharmaceutics Review</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%2520Injection_admincorres.PDF">Administrative Documents & Correspondence</a></p><p><strong>Byetta (exenatide) - NDA 21-773</strong></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_approv.PDF">Approval Letter & Package (April 28, 2005)</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_medr.PDF">Medical Review</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_statr.PDF">Statistical Review</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_biopharmr.PDF">Clinical Pharmacology & Biopharmaceutics Review</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_admincorres.PDF">Administrative Documents & Correspondence</a></p><p><strong>Bydureon (exenatide ER) - NDA 22-200</strong></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000Approv.pdf">Approval Letter (January 27, 2012)</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000OtherActionLtrs.pdf">Other Action Letters (Complete Response)</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000SumRedt.pdf">Summary Review</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000Rems.pdf">REMS</a></p><p>* <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022200Orig1s000Admincorresedt.pdf">Administrative Correspondence</a></p><p><strong>SEC Filings & Financial Documents</strong></p><p>* <a href="https://www.sec.gov/Archives/edgar/data/881464/000110465906007417/a06-4671_1ex99d1.htm">Amylin 2005 Results Press Release (Ex-99.1, 8-K)</a></p><p>* <a href="https://www.sec.gov/Archives/edgar/data/881464/000110465908005085/a08-3824_1ex99d1.htm">Amylin 2007 Results Press Release (Ex-99.1)</a></p><p>* <a href="https://www.sec.gov/Archives/edgar/data/881464/000119312512072788/d260205d10k.htm">Amylin 2011 Form 10-K (Net Product Sales)</a></p><p>* <a href="https://www.sec.gov/divisions/corpfin/cf-noaction/2009/icahnassociates032709-sec14-incoming.pdf">Carl Icahn SEC Filing (Schedule 13D)</a></p><p><strong>Proxy Fight & Legal Documents</strong></p><p>* <a href="https://www.fiercebiotech.com/biotech/letter-from-carl-icahn-to-amylin-pharmaceutical">Carl Icahn Letter to Amylin (April 15, 2009)</a></p><p>* <a href="https://www.fiercebiotech.com/biotech/amylin-letter-to-carl-icahn">Amylin Response to Icahn (April 20, 2009)</a></p><p>* <a href="https://cvn.com/proceedings/police-fund-v-bradbury-amylin-trial-2009-05-04">Police Fund v. Bradbury (Amylin) Trial (May 4, 2009)</a></p><p>* <a href="https://investor.lilly.com/static-files/51a2a9a3-6b73-4e44-9f48-c22133624708">Lilly Litigation Ruling (May 25, 2011)</a></p><p><strong>II. ORAL HISTORY & INTERVIEWS</strong></p><p>* <a href="https://library.ucsd.edu/dc/object/bb2187116q/_1_1.pdf">Howard Greene Oral History (UCSD Library, October 8, 2008)</a> - Primary source for Hybritech founding, Ted Greene’s background, and early Amylin history</p><p><strong>III. NEWS & TRADE PRESS</strong></p><p><strong>2000</strong></p><p>* <a href="https://www.cbsnews.com/news/the-rumsfeld-resume/">“The Rumsfeld Resume” - CBS News (December 28, 2000)</a> - Donald Rumsfeld’s board tenure at Amylin (1991-1996)</p><p>* <a href="https://www.forbes.com/forbes/2000/0724/6603205a.html">“Roller Coasting” - Forbes (July 24, 2000)</a> - Joe Cook narrative, J&J partnership collapse</p><p><strong>2005</strong></p><p>* <a href="https://www.nytimes.com/2005/03/19/business/investing-for-a-profit-and-a-daughters-health.html">“Investing for a Profit and a Daughter’s Health” - NYT (March 19, 2005)</a> - Allen Andersson investment story, “tablecloth deal”</p><p><strong>2006</strong></p><p>* <a href="https://www.nytimes.com/2006/03/02/business/worldbusiness/02iht-drug.html">“Diabetics see hope (and weight loss) in new drug” - NYT (March 2, 2006)</a> - “Lizzie” nickname, patient testimonials</p><p>* <a href="https://www.nytimes.com/2006/06/22/business/22diabetes.html">“4 Diabetes Drugs Are Seen Raising Hope and Profit” - NYT (June 22, 2006)</a> - Manufacturing shortage, 400,000+ patients</p><p>* <a href="https://www.heritage.org/public-health/commentary/dont-kill-life-saving-drugs">“Don’t kill off life-saving drugs” - Heritage Foundation (August 15, 2006)</a> - Policy perspective on Byetta’s potential impact</p><p>* <a href="https://diatribe.org/diabetes-medications/byetta-craze-first-salvo-promising-new-line-drugs">“Byetta Craze Is First Salvo in Promising New Line of Drugs” - diaTribe</a> - ADA conference chaos, “one man cried”</p><p><strong>2007</strong></p><p>* <a href="https://www.diabetesincontrol.com/dr-john-engs-research-found-that-the-saliva-of-the-gila-monster-contains-a-hormone-that-treats-diabetes-better-than-any-other-medicine/">Dr. John Eng Profile - Diabetes In Control (September 18, 2007)</a> - Eng’s discovery story, patent struggles, Amylin vs. Lilly negotiations</p><p><strong>2008</strong></p><p>* <a href="https://www.biospace.com/xenome-ltd-names-b-ian-t-nisbet-phd-b-as-ceo">Xenome/Amylin Partnership - BioSpace (February 5, 2008)</a> - Venom peptide library partnership</p><p><strong>2009</strong></p><p>* <a href="https://www.sandiegouniontribune.com/2009/10/10/eastbourne-capital-sells-entire-stake-in-amylin/">Eastbourne Capital Sells Stake - San Diego Union-Tribune (October 10, 2009)</a> - End of Eastbourne activist campaign</p><p>* <a href="https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/survey-additional-diabetes-drugs-dpp-iv-inhibitors-needed">Survey: Additional Diabetes Dru...</a></p>
3 total episodes available
Similar Podcasts
Discover related shows you might enjoy
The Long Run with Luke Timmerman
Timmerman Report
The Readout Loud
STAT
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
a16z Podcast
Andreessen Horowitz
Complex Systems with Patrick McKenzie (patio11)
Patrick McKenzie
BioCentury This Week
BioCentury
Core Memory
Ashlee Vance
Odd Lots
Bloomberg
Uncapped with Jack Altman
Alt Capital
The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch
Harry Stebbings
Invest Like the Best with Patrick O'Shaughnessy
Colossus | Investing & Business Podcasts
Conversations with Tyler
Mercatus Center at George Mason University
No Priors: Artificial Intelligence | Machine Learning | Technology | Startups
Conviction
Prof G Markets
Vox Media Podcast Network
All-In with Chamath, Jason, Sacks & Friedberg
All-In Podcast, LLC
Deep-dive analytics for Approved
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Approved?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.